Three of the patients, patients 1, 2, and 3, had advanced GIST originating from the small intestine with a primary mutation of KIT 11 and were treated with ripretinib 150 mg QD as a second-line treatment (Table 5). This evidence concerns the gene KIT and gastrointestinal stromal tumor.